tradingkey.logo

Sol Gel Technologies Ltd

SLGL
查看详细走势图
65.780USD
+1.080+1.67%
收盘 02/06, 16:00美东报价延迟15分钟
183.25M总市值
亏损市盈率 TTM

Sol Gel Technologies Ltd

65.780
+1.080+1.67%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+1.67%

5天

+2.43%

1月

+23.55%

6月

+350.24%

今年开始到现在

+56.10%

1年

+943.80%

查看详细走势图

TradingKey Sol Gel Technologies Ltd股票评分

单位: USD 更新时间: 2026-02-06

操作建议

Sol Gel Technologies Ltd当前公司基本面数据相对非常健康,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名103/392位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价110.00。中期看,股价处于上升通道。近一个月,市场表现较强,技术面和基本面综合得分较高,较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Sol Gel Technologies Ltd评分

相关信息

行业排名
103 / 392
全市场排名
232 / 4521
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Sol Gel Technologies Ltd亮点

亮点风险
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
业绩高增长
公司营业收入稳步增长,连续3年增长197.14%
业绩增长期
公司处于发展阶段,最新年度总收入11.54M美元
估值低估
公司最新PE估值-20.39,处于3年历史低位
机构减仓
最新机构持股617.10K股,环比减少44.99%
景顺投资公司持仓
明星投资者景顺投资公司持仓,最新持仓市值0.00

分析师目标

根据 1 位分析师
买入
评级
110.000
目标均价
+66.79%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Sol Gel Technologies Ltd新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Sol Gel Technologies Ltd简介

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
公司代码SLGL
公司Sol Gel Technologies Ltd
CEO
网址http://www.sol-gel.com
KeyAI